D&D Pharmatech Inc. (347850) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for D&D Pharmatech Inc. (347850:KRX), powered by AI.

Current Price
₩70,800
P/E Ratio
-131.7
Market Cap
3.1T
Sector
Healthcare
What is the D&D Pharmatech Inc. stock price forecast?

D&D Pharmatech Inc. is currently trading at ₩70,800. View real-time AI analysis on Alpha Lenz.

What is D&D Pharmatech Inc. insider trading activity?

View the latest insider trading data for D&D Pharmatech Inc. on Alpha Lenz.

What is D&D Pharmatech Inc.'s P/E ratio?

D&D Pharmatech Inc.'s P/E ratio is -131.7.

D&D Pharmatech Inc.

KRX · 347850
₩70,800+600(+0.85%)Market closedKRX regular session 09:00–15:30 KST
Ask about D&D Pharmatech Inc.'s future dividend policy...
Alpha Chat Insight

D&D Pharmatech Inc. trades at a P/E of -131.7 (undervalued) with modest ROE of -31.5%. 3Y revenue CAGR of 91.6% highlights clear growth momentum.

Ask for details

Company Overview

D&D Pharmatech Inc. is a biotechnology company dedicated to the development and commercialization of innovative therapeutic solutions. The company primarily focuses on advancing treatments for central nervous system disorders, metabolic diseases, and fibrotic diseases, with a robust pipeline of drug candidates in various stages of clinical trials. Utilizing cutting-edge scientific research and strategic partnerships, D&D Pharmatech aims to address unmet medical needs, enhancing the lives of patients while contributing to advancements in medical science. With operations that span drug discovery to clinical development, the company plays a significant role in the biotechnology sector, impacting both healthcare providers and patients. By leveraging proprietary technology platforms, D&D Pharmatech is positioned at the forefront of biopharmaceutical innovation, reinforcing its commitment to driving transformative medicine. Its contributions to the biotech industry are marked by a strong emphasis on research and development, exemplifying the dynamic nature of the sector and its potential to disrupt traditional treatment paradigms.

CEO이슬기
SectorHealthcare
IndustryBiotechnology
Employees21

Company Statistics

FY 2025

Profile

₩3,101,333,607,600Market Cap
₩4,297,604,940Revenue
43.80MShares Out
21Employees

Margins

100.00%Gross
-680.59%EBITDA
-790.97%Operating
-579.42%Pre-Tax
-557.98%Net

Valuation

-131.67P/E
39.01P/B
721.64EV/Sales
-105.10EV/EBITDA
-146.27P/FCF

Growth (CAGR)

91.65%Rev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-24.59%ROA
-31.49%ROE
-25.05%ROIC

Financial Health

₩32,883,741,890Cash & Cash Equivalents
₩-14,323,435,760Net Debt
23.50%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

D&D Pharmatech Inc. (ticker: 347850) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 21 employees. Market cap is $3.1T.

The current price is ₩70,800 with a P/E ratio of -131.67x and P/B of 39.01x.

ROE is -31.49% and operating margin is -790.97%. Annual revenue is $4.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
D&D Pharmatech Inc. (Healthcare) Stock Forecast & Analysis ₩70,800 | Alpha Lenz